{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for pantothenic root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
Possibly Marketed Outside US
First approved in 2013
Source:
BLA125421
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M020
(2015)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Conditions:
Status:
Possibly Marketed Outside US
Source:
Laser Rejuvenation restoring damage skin by Universal Cosmetic Co., Ltd
Source URL:
First approved in 2003
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
ACETYL HEXAPEPTIDE-8 (ARGIRELINE®), a hexapeptide Ac-EEMQRR-NH2, is an anti-wrinkling agent. It significantly inhibits neurotransmitter release with a potency similar to that of botulinum toxin. ACETYL HEXAPEPTIDE-8 (ARGIRELINE®) is a mimic of the N-terminal end of SNAP-25 which competes with SNAP-25 for a position in the SNARE complex, thereby modulating its formation. If the SNARE complex is slightly destabilized, the vesicle can not release neurotransmitters efficiently and therefore muscle contraction is attenuated, preventing the formation of lines and wrinkles.
Status:
Possibly Marketed Outside US
First approved in 1999
Source:
BLA103665
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 1990
Source:
BLA103249
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02226887: Phase 4 Interventional Unknown status Loop Ileostomy Closure
(2014)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
